Renal Adenocarcinoma (Kidney Cancer) in Dogs

Open table of contents

When to visit the vet?

Non-urgent see a veterinarian within 2–3 days

?

If the condition worsens / symptoms persist, consult a veterinarian.

Download/Print

Definition

Renal adenocarcinoma, also known as kidney cancer, is a malignant neoplasia that develops from the glandular epithelial cells of the renal parenchyma. This tumor type belongs to the group of primary renal tumors and accounts for approximately 60–85% of all malignant renal neoplasias in dogs. Histologically, adenocarcinoma is characterized by atypical epithelial cells that form gland-like structures and exhibit an invasive growth pattern.

The most important facts at a glance

Renal adenocarcinoma in dogs represents a rare but aggressive tumor disease that primarily affects older animals. The etiology is multifactorial, with genetic and environmental influences. Clinically, the disease often presents only in advanced stages with nonspecific symptoms such as weight loss, lethargy, and hematuria, making early detection difficult.

Diagnosis requires a multimodal approach consisting of clinical examination, laboratory diagnostics, imaging procedures, and histopathological assessment. Comprehensive staging is essential for treatment planning and prognosis assessment. Surgical removal of the tumor through nephrectomy remains the most important treatment option for localized tumors, while adjuvant treatments such as chemotherapy or targeted therapies may be considered in advanced disease.

The prognosis varies considerably depending on tumor stage, histological grade, and success of surgical resection. Structured follow-up care with regular clinical, laboratory diagnostic, and imaging examinations is essential to detect recurrences early and monitor renal function. Supportive measures, particularly adapted nutrition, contribute significantly to maintaining quality of life.

Despite advances in diagnostics and therapy, renal adenocarcinoma remains a challenge in veterinary oncology. Research into new molecular markers and innovative therapeutic approaches, inspired by insights from human medicine, offers hope for improved treatment outcomes in the future.

Causes

Compared to other cancers in dogs, renal tumors are relatively rare, with an incidence of less than 2% of all canine neoplasias. Nevertheless, they present a particular challenge due to their aggressive nature and often late diagnosis. Renal adenocarcinoma can occur unilaterally or bilaterally, with unilateral involvement being more common. The disease primarily affects older dogs with an average age at diagnosis of 8 to 9 years, although dogs of any age can be affected.

Notably, there is a similarity between canine kidney cancer and renal cell carcinoma in humans, making this disease interesting for comparative oncological research. Both tumor types show similar molecular signaling pathways and alterations, making dogs a valuable model for researching new therapeutic approaches.

  • Genetic predisposition: Current studies suggest that certain dogs may have a genetic predisposition to renal adenocarcinomas. Mutations in oncogenic signaling pathways (e.g., in genes such as VHL or HIF) play a role, analogous to findings in human medicine.
  • Environmental factors: Exposure to certain chemicals or chronic kidney disease can promote the development of a renal tumor.

Breed aspects: Although no clear clustering is known, some larger breeds such as German Shepherds, Golden Retrievers, or Bernese Mountain Dogs have occasionally been reported to have a higher incidence.

The exact etiology of renal adenocarcinoma in dogs is multifactorial and not yet fully understood. Current research findings point to a complex interplay of genetic and environmental factors:

Genetic predisposition plays a crucial role in the development of kidney cancer. Recent molecular genetic studies have shown that mutations in tumor suppressor genes such as VHL (von Hippel-Lindau) and oncogenes such as MET can contribute to tumor development, similar to humans. These genetic alterations lead to dysregulation of cellular signaling pathways, particularly the HIF (hypoxia-inducible factor) signaling pathway, resulting in uncontrolled cell growth and increased angiogenesis.

Chronic kidney disease can increase the risk of developing renal adenocarcinoma. Prolonged inflammatory processes and repeated tissue damage can lead to DNA damage and promote malignant transformation. Similarly, nephrotoxic substances such as certain heavy metals, pesticides, or medications can damage renal tissue and contribute to cancer development in the long term.

Although no clear breed predisposition has been proven, a certain clustering is observed in medium to large dog breeds such as German Shepherds, Golden Retrievers, Labrador Retrievers, and Bernese Mountain Dogs. This could indicate breed-specific genetic factors that increase susceptibility to renal tumors.

Hormonal factors are also being discussed, as some studies have found a higher incidence in male dogs, which could indicate a possible influence of sex hormones. However, the data on this are not yet conclusive.

Symptoms

The clinical manifestations of renal adenocarcinoma in dogs are often nonspecific and develop insidiously, making early detection difficult. Symptomatology can vary depending on tumor stage, size, and degree of metastasis:

In early stages, the disease often runs asymptomatically, as the healthy kidney can compensate for function. However, with progressive tumor growth, signs of illness can increasingly appear. The most common symptoms include lethargy, reduced appetite up to anorexia, and progressive weight loss. These nonspecific signs are often initially attributed to the animal’s age, leading to delays in diagnosis.

Hematuria (blood in urine) is a characteristic symptom in approximately 20–40% of affected dogs and results from tumor invasion into the renal pelvis or urinary tract. Blood admixture can occur intermittently and be macroscopically visible or only microscopically detectable. In advanced cases, flank pain may occur, manifesting as sensitivity to touch in the kidney area or behavioral changes such as reluctance to move.

In larger tumors, a palpable mass in the cranial abdomen can be detected. In approximately 30% of cases, affected dogs develop secondary arterial hypertension, which can lead to further clinical manifestations such as retinal hemorrhages or neurological symptoms. Paraneoplastic syndromes such as hypercalcemia, polycythemia, or fever of unknown origin can also occur and are due to the production of bioactive substances by the tumor.

In advanced disease with metastasis formation, additional organ-specific symptoms may occur, particularly cough, dyspnea, or exercise intolerance in pulmonary metastases, or neurological deficits in bone metastases. Approximately 50% of dogs already show signs of metastasis at initial presentation, most commonly in the lungs, regional lymph nodes, liver, and bones.

Many courses begin nonspecifically. A combination of unilateral kidney enlargement (renomegaly, abdominal mass) + increased thirst, increased urination, and possibly hematuria should suggest a renal tumor.

Diagnosis

  • Imaging procedures such as ultrasound, X-ray, or CT scans to identify tumors in the kidneys
  • Biopsy of the tumor to confirm the diagnosis and assess tumor grade
  • Laboratory tests to check kidney function and the general condition of the dog

Diagnosis of renal adenocarcinoma in dogs requires a systematic approach with various complementary examination methods. Early and precise diagnosis is crucial for treatment planning and prognosis assessment.

Clinical examination forms the starting point of diagnostics. On palpation of the abdomen, an enlarged, firm, or painful kidney may be noticed. Auscultation of the thorax can provide indications of pulmonary metastases. Laboratory tests include a complete blood count, serum biochemistry, and urinalysis. Typical findings may include normochromic, normocytic anemia, leukocytosis, elevated kidney parameters (urea, creatinine) in advanced disease, and hematuria in urine sediment. In some patients, elevated calcium levels may also occur as a paraneoplastic phenomenon.

Imaging plays a central role in diagnostics. Abdominal ultrasound is usually the first imaging method and can show changes in size, shape, and echotexture of the kidney. Typically, renal adenocarcinomas appear as heterogeneous, often hyperechoic masses with irregular margins and possible cystic or necrotic areas. Doppler sonography can also provide information about tumor vascularization and possible invasion into the renal vessels or caudal vena cava.

For comprehensive staging, further imaging procedures such as thoracic X-rays (for metastasis screening), computed tomography (CT), or magnetic resonance imaging (MRI) are essential. These modalities enable more precise assessment of local tumor extent, vascular invasion, and potential metastases. In particular, contrast-enhanced CT has proven valuable for preoperative planning and staging.

Definitive diagnosis requires histopathological examination. This can be done through fine-needle aspiration, Tru-Cut biopsy, or after surgical removal of the tumor. Fine-needle aspiration is minimally invasive but often provides only limited diagnostic information and carries the risk of tumor spread. A larger biopsy (Tru-Cut biopsy) provides more tissue for histological assessment but is more invasive and carries similar risks. Histopathological examination after nephrectomy provides the most comprehensive information about tumor type, grade of differentiation, and invasiveness.

Molecular diagnostics is gaining increasing importance. Immunohistochemical examinations can detect specific tumor markers such as cytokeratin, vimentin, or CD10 and contribute to more precise classification. Genetic analyses can identify prognostically relevant mutations and reveal potential targets for targeted therapies.

Therapy

  • Surgical removal: A nephrectomy (removal of the affected kidney) is often the first choice, provided the second kidney is functional and the tumor has not yet formed distant metastases.
  • Chemotherapy: Certain protocols (e.g., based on doxorubicin) are used depending on the tumor stage. Efficacy is still the subject of current studies.
  • Targeted therapies: Following advances in human medicine, inhibitors of signaling pathways (tyrosine kinase inhibitors) are being researched.
  • Immunotherapy: Initial approaches in which immune checkpoint inhibitors are tested show potential but need further evaluation.

Supportive therapies to relieve pain and improve quality of life.

Treatment of renal adenocarcinoma in dogs is based on a multimodal approach, with surgical intervention remaining the most important pillar. Treatment decisions must be made individually, taking into account tumor stage, the patient’s general condition, and available technical resources.

Surgical removal of the tumor through radical nephrectomy is the treatment of choice for localized, non-metastatic tumors. This involves removing the affected kidney along with the surrounding fat capsule, the proximal ureter, and regional lymph nodes. For very large tumors or suspected vascular invasion, an extended approach may be necessary. The surgery should be performed by an experienced surgeon, as intraoperative complications such as severe bleeding can occur due to the rich vascularization of the kidney. A prerequisite for nephrectomy is adequate function of the contralateral kidney, which should be ensured preoperatively through laboratory tests and imaging procedures.

In selected cases with small, well-defined tumors, partial nephrectomy (kidney-sparing surgery) may be considered. This technique is more technically demanding but can be advantageous in bilateral tumors or in patients with impaired renal function. Newer minimally invasive techniques such as laparoscopic nephrectomy are gaining increasing importance and can contribute to faster postoperative recovery.

Adjuvant chemotherapy is controversially discussed, as its efficacy in canine renal adenocarcinoma is not clearly established. However, it may be considered in patients at high risk of metastasis, incomplete tumor resection, or existing metastases. Protocols based on doxorubicin, carboplatin, or mitoxantron are most commonly used, with variable response rates. A combination of different chemotherapeutic agents may be beneficial in some cases.

Targeted therapies, particularly tyrosine kinase inhibitors such as toceranib (Palladia®) or masitinib, represent a promising option. These medications inhibit specific signaling pathways important for tumor growth and angiogenesis. Studies have shown that they can lead to disease stabilization in some dogs with advanced kidney cancer. Identification of predictive biomarkers could enable better patient selection for this form of therapy in the future.

Immunotherapy with checkpoint inhibitors is still in the experimental stage but shows promising results in preclinical studies. These medications reactivate the body’s own immune system to recognize and combat tumor cells. Initial clinical studies with antibodies in dogs with various tumor types, including renal carcinomas, are currently underway.

Supportive measures are an essential component of the treatment concept. These include adapted nutrition (kidney-friendly diet in cases of impaired renal function), adequate pain therapy, and treatment of comorbidities. In patients with advanced disease, palliative care is the priority, with the goal of maintaining quality of life for as long as possible.

Prognosis and follow-up care

The prognosis depends on the stage of the disease, the size and location of the tumor, and the response to treatment. Tumors diagnosed and treated early generally have a better prognosis. However, kidney cancer can often only be diagnosed at an advanced stage, which complicates treatment and prognosis. In such cases, treatment focuses on slowing disease progression and maintaining the dog’s quality of life for as long as possible. Survival rates vary greatly depending on the individual case, and follow-up care is important to detect and treat relapses or metastases early.

Aftercare

  • Regular check-ups: Blood and urine tests, imaging procedures (X-ray, ultrasound) at intervals of 3 to 6 months.
  • Nutrition and Management: A dietary adjustment (kidney-friendly feeding) can help support the function of the remaining kidney.
  • Quality of Life: Special attention to possible symptoms of kidney weakness (e.g., increased thirst, weight loss) and early therapeutic interventions contribute to an improved quality of life.

The prognosis for dogs with renal adenocarcinoma varies considerably and depends on several factors, including tumor stage at diagnosis, histological grade of differentiation, presence of metastases, and success of surgical resection. Careful follow-up care is essential to detect recurrences early and optimize quality of life.

In dogs with localized tumors that could be completely surgically removed, median survival time is between 12 and 24 months. Factors associated with a more favorable prognosis include low histological grade of malignancy, absence of vascular invasion, and negative resection margins. In contrast, patients with advanced disease, particularly in the presence of distant metastases, have a significantly worse prognosis with median survival times of 3 to 6 months despite multimodal therapy.

The histological subtype of adenocarcinoma may have prognostic relevance. Papillary and tubular variants tend to show less aggressive behavior than solid or sarcomatoid subtypes. Molecular markers such as the expression of VEGF (Vascular Endothelial Growth Factor), Ki-67, or p53 are increasingly being investigated as potential prognostic indicators.

A structured follow-up program is essential for all patients after treatment of renal adenocarcinoma. In the first six months after surgery, monthly follow-up examinations are recommended; thereafter, intervals can be extended to three to six months if the course is stable. Each follow-up examination should include a thorough clinical examination, blood and urine analyses, and imaging procedures.

Monitoring renal function is particularly important, as the remaining kidney must assume the entire excretory function. Regular determinations of urea, creatinine, electrolytes, and urine-specific gravity can reveal early signs of renal dysfunction. Blood pressure measurement should also be part of routine monitoring, as hypertension is a common complication.

Imaging procedures for metastasis screening include thoracic X-rays every three months in the first year and abdominal ultrasound examinations to assess the contralateral kidney and possible local recurrences. If metastases are suspected or in high-risk patients, further examinations such as CT or MRI may be indicated.

Nutritional counseling is an important aspect of follow-up care. An individually adapted diet can support the function of the remaining kidney and improve quality of life. In cases of impaired renal function, a phosphorus- and protein-reduced diet is recommended, supplemented by adequate fluid intake.

If signs of recurrence or metastasis appear, treatment options must be re-evaluated. In some cases, local treatment procedures such as radiation therapy for isolated metastases or systemic therapies such as chemotherapy or targeted medications may be considered. Palliative care with a focus on pain management and maintaining quality of life is becoming increasingly important in advanced stages.

Prevention

Renal adenocarcinoma cannot be reliably prevented, as the causes are often unclear. Nevertheless, preventive measures can support kidney health and facilitate early diagnosis. Regular preventive examinations, especially in older dogs, should include blood and urine analyses. A balanced diet, adequate water intake, and avoidance of nephrotoxins (e.g., certain medications, toxic plants) are important. X-ray or ultrasound checks can help detect changes early in at-risk patients. Owners should watch for symptoms such as weight loss, blood in urine, or increased drinking and have these examined by a veterinarian immediately.

Outlook on current research

Research on renal adenocarcinoma in dogs is continuously evolving, with several promising directions being pursued. The One Health approach, which uses the parallels between human and canine tumors, is gaining increasing importance and promotes knowledge transfer between human and veterinary medicine.

In the field of molecular oncology, genetic and epigenetic changes underlying canine renal adenocarcinoma are being intensively researched. Next-generation sequencing technologies enable the identification of driver mutations and molecular signatures that could serve as prognostic markers or therapeutic targets. Comparative genomic studies have already revealed remarkable similarities between canine and human renal cell carcinomas, particularly regarding alterations in the VHL-HIF signaling pathway and the MET signaling cascade.

In the field of imaging, new techniques are being developed that enable earlier and more precise diagnosis. Functional imaging procedures such as dynamic contrast-enhanced MRI or PET-CT with tumor-specific tracers can provide additional information about tumor biology and metabolism. The application of artificial intelligence to analyze radiological images promises improved detection and characterization of renal lesions.

In the field of minimally invasive surgery, advanced laparoscopic and robot-assisted techniques for nephrectomy and partial nephrectomy are being further developed. These procedures aim to reduce operative trauma, achieve faster recovery times, and improve cosmetic results while maintaining oncological principles.

Immunotherapy represents one of the most promising research areas. Clinical studies with checkpoint inhibitors such as anti-PD-1/PD-L1 antibodies in dogs with various tumor types, including renal carcinomas, show encouraging results. New approaches such as CAR-T cell therapies or tumor-specific vaccines are in preclinical development phases and could expand the therapeutic arsenal in the future.

In the field of targeted therapies, new generations of tyrosine kinase inhibitors with improved specificity and reduced toxicity are being developed. The combination of different targeted agents or their integration into multimodal treatment concepts is also being investigated. Biomarker-guided treatment decisions based on the molecular characterization of individual tumors could pave the way for personalized oncology in veterinary medicine.

Last but not least, research into the tumor microenvironment is gaining increasing importance. The interactions between tumor cells, immune cells, and stromal components significantly influence tumor growth, metastasis, and treatment response. A better understanding of these complex interactions could open up new therapeutic strategies that target not primarily the tumor cells but their environment.

These diverse research approaches fuel hope for improved diagnostic and therapeutic options for dogs with renal adenocarcinoma in the future. Close collaboration between basic researchers, clinical veterinary oncologists, and human physicians will be crucial to drive innovation and ultimately improve the prognosis of affected patients.

Frequently asked questions (FAQs)

1. What is Renal Adenocarcinoma in Dogs?
Renal adenocarcinoma is a malignant tumor that arises from the epithelial cells of the kidney tissue. It can grow locally invasively and spread to other organs. According to Withrow & MacEwen's Small Animal Clinical Oncology (6th edition), renal tumors are among the rarer cancers in dogs but require early diagnosis.
2. What Symptoms may Indicate Kidney Cancer in Dogs?
Initially, nonspecific signs such as decreased appetite, weight loss, and increased thirst often occur. Later, bloody urine (hematuria), lethargy, flank pain, or a palpable tumor in the abdomen may appear. petsvetcheck.de strongly recommends veterinary examination for these symptoms.
3. How is a Kidney Tumor Diagnosed?
- Blood and urine tests: Checking kidney function and tumor markers. - Imaging: Ultrasound, X-ray, CT, or MRI for precise tumor localization and exclusion of metastases. - Tissue sample (biopsy): Histopathological examination to confirm diagnosis. Standard works such as the BSAVA Manual of Canine and Feline Oncology describe fine-needle aspiration as a helpful method when location permits.
4. What Treatment Options are Available?
- Surgical removal (nephrectomy): First choice if only one kidney is affected. - Chemotherapy: in advanced cases or with high risk of metastasis. - Immunotherapy and targeted therapies: Are increasingly being researched. According to Veterinary Ophthalmology (Gelatt et al.), an interdisciplinary approach is worthwhile when a tumor has already spread to other organ systems.
5. Is Surgery Always Possible?
If the tumor is confined to one kidney and the other kidney is healthy, complete removal is often feasible and offers a chance of cure or long-term control. In bilateral changes or already advanced metastases, surgery may be limited or only performed palliatively.
6. What is the prognosis?
The prognosis depends heavily on tumor stage. If adenocarcinoma is detected early and can be completely removed, the dog has good chances of several tumor-free years. In metastatic tumors, the prognosis deteriorates significantly. In Withrow & MacEwen's Small Animal Clinical Oncology , a median survival of 6 to 16 months is described, depending on metastasis.
7. Can Kidney Tumors Spread to other Organs?
Yes, renal adenocarcinomas frequently spread to the lungs, liver, and local lymph nodes. Therefore, regular follow-up examinations (e.g., thoracic X-ray, ultrasound) after surgery are essential to detect metastases early.
8. Are Certain Dog Breeds more Frequently Affected?
There is no clearly established breed preference, but some studies (e.g., in larger breeds such as German Shepherds or Golden Retrievers) discuss a possible clustering. This may be due to genetic factors or a higher likelihood of examinations in certain breeds.
9. What Follow-Up Measures are Important?
- Regular check-ups: Blood pressure measurement, blood and urine tests, imaging procedures. - Adapted diet: Special kidney diets relieve the remaining kidney. - Observation of the general condition: Seek veterinary help early if there are any changes. On petsvetcheck.de practical advice is given on how to handle dogs after surgery, e.g. calming down, wound care and monitoring the amount of water they drink.
10. What Role Does Nutrition Play in Dogs with Kidney Cancer?
A balanced, kidney-supportive diet can positively influence the organ function of the healthy (or remaining) kidney. Proteins should be provided in appropriate amounts, while excess minerals (especially phosphorus) should be reduced. According to Slatter's Textbook of Small Animal Surgery , an individually adapted diet can improve quality of life and slow the progression of kidney disease.